JP2020528075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528075A5 JP2020528075A5 JP2020516785A JP2020516785A JP2020528075A5 JP 2020528075 A5 JP2020528075 A5 JP 2020528075A5 JP 2020516785 A JP2020516785 A JP 2020516785A JP 2020516785 A JP2020516785 A JP 2020516785A JP 2020528075 A5 JP2020528075 A5 JP 2020528075A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- apc
- days
- daily
- once daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 41
- 206010041349 Somnolence Diseases 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 12
- UCTRAOBQFUDCSR-SECBINFHSA-N [(2r)-2-amino-3-phenylpropyl] carbamate Chemical compound NC(=O)OC[C@H](N)CC1=CC=CC=C1 UCTRAOBQFUDCSR-SECBINFHSA-N 0.000 claims 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 201000003631 narcolepsy Diseases 0.000 claims 4
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 3
- 208000032140 Sleepiness Diseases 0.000 claims 3
- 230000037321 sleepiness Effects 0.000 claims 3
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
- 230000037007 arousal Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514176P | 2017-06-02 | 2017-06-02 | |
| US62/514,176 | 2017-06-02 | ||
| PCT/US2018/035532 WO2018222954A1 (en) | 2017-06-02 | 2018-06-01 | Methods and compositions for treating excessive sleepiness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528075A JP2020528075A (ja) | 2020-09-17 |
| JP2020528075A5 true JP2020528075A5 (enExample) | 2021-07-26 |
Family
ID=64455104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516785A Pending JP2020528075A (ja) | 2017-06-02 | 2018-06-01 | 過度の眠気を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US10959976B2 (enExample) |
| EP (1) | EP3630072A4 (enExample) |
| JP (1) | JP2020528075A (enExample) |
| KR (3) | KR20200016889A (enExample) |
| CN (1) | CN111201014A (enExample) |
| AU (1) | AU2018278332B2 (enExample) |
| BR (1) | BR112019025286A2 (enExample) |
| CA (1) | CA3065522A1 (enExample) |
| MX (1) | MX390786B (enExample) |
| MY (1) | MY203401A (enExample) |
| PH (1) | PH12019502723A1 (enExample) |
| WO (1) | WO2018222954A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| EP3630072A4 (en) | 2017-06-02 | 2021-03-10 | Jazz Pharmaceuticals Ireland Limited | METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness |
| JP7553453B2 (ja) | 2019-03-01 | 2024-09-18 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| WO2021001457A1 (en) * | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| US20240358668A1 (en) * | 2021-09-03 | 2024-10-31 | Axsome Therapeutics, Inc. | Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| AU2023375326A1 (en) * | 2022-11-07 | 2025-05-22 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| EP4626417A1 (en) * | 2022-11-30 | 2025-10-08 | Axsome Therapeutics | Methods and compositions for improving driving performance |
| US11771666B1 (en) | 2022-12-30 | 2023-10-03 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12005036B1 (en) | 2022-12-30 | 2024-06-11 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| CN120641090A (zh) * | 2022-12-30 | 2025-09-12 | 阿克苏姆马耳他有限公司 | 向哺乳期女性施用索安非托的方法 |
| US12102609B2 (en) | 2022-12-30 | 2024-10-01 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12036194B1 (en) | 2022-12-30 | 2024-07-16 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12064411B1 (en) * | 2022-12-30 | 2024-08-20 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| US12090126B2 (en) | 2022-12-30 | 2024-09-17 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| AU2024278948A1 (en) * | 2023-05-30 | 2025-12-11 | Axsome Therapeutics, Inc. | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness |
| WO2025042959A1 (en) * | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025064549A1 (en) * | 2023-09-18 | 2025-03-27 | Axsome Therapeutics, Inc. | Solriamfetol for improving cognitive health in apnea patients |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2939660A1 (de) | 1979-09-29 | 1981-04-16 | Basf Ag, 6700 Ludwigshafen | Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| CZ285829B6 (cs) | 1993-06-10 | 1999-11-17 | Eli Lilly And Company | Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce |
| DE9311004U1 (de) | 1993-07-23 | 1993-10-14 | Mauser-Werke GmbH, 50321 Brühl | Palettencontainer |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| ES2170878T3 (es) | 1996-10-10 | 2002-08-16 | Sk Corp | Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles. |
| WO1998017636A1 (en) | 1996-10-22 | 1998-04-30 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| WO2002067921A1 (en) | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating bipolar disorder |
| WO2002067926A1 (en) | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating movement disorders |
| DK1399144T3 (da) | 2001-02-27 | 2006-07-24 | Ortho Mcneil Pharm Inc | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af angstforstyrrelser |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| EP1534238A1 (en) | 2002-07-29 | 2005-06-01 | ALZA Corporation | Formulations and dosage forms for controlled delivery of topiramate |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| US20050203130A1 (en) | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CN101132787A (zh) | 2004-10-28 | 2008-02-27 | Sk株式会社 | 抑郁的辅助疗法 |
| CN101217949B (zh) | 2005-06-08 | 2012-10-17 | 爱思开生物制药株式会社 | 治疗睡眠-清醒病症 |
| DE602006012670D1 (de) | 2005-06-22 | 2010-04-15 | Sk Holdings Co Ltd | Behandlung der sexuellen dysfunktion |
| JP5094720B2 (ja) | 2005-07-26 | 2012-12-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | サブスタンス関連障害を処置する方法 |
| CA2673487A1 (en) | 2006-10-13 | 2008-04-24 | Janssen Pharmaceutica Nv | Phenylalkylamino carbamate compositions |
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| CA2765463C (en) | 2009-06-22 | 2018-10-09 | Moise A. Khayrallah | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
| RU2556585C2 (ru) | 2009-11-06 | 2015-07-10 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома дефицита внимания и гиперактивности |
| WO2011139271A1 (en) | 2010-05-04 | 2011-11-10 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| EP2392325A1 (en) | 2010-06-04 | 2011-12-07 | Universitätsklinikum Münster | Compounds for the prevention and/or treatment of osteoarthrosis |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| DK2968208T3 (da) | 2013-03-13 | 2022-08-22 | Jazz Pharmaceuticals Ireland Ltd | Behandling af kataplexi |
| WO2015006685A1 (en) | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International Iii Limited | Promotion of smoking cessation |
| TW201919605A (zh) | 2013-07-18 | 2019-06-01 | 南韓商愛思開生物製藥股份有限公司 | 肥胖之治療 |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| EP3630072A4 (en) | 2017-06-02 | 2021-03-10 | Jazz Pharmaceuticals Ireland Limited | METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
-
2018
- 2018-06-01 EP EP18810236.2A patent/EP3630072A4/en active Pending
- 2018-06-01 MY MYPI2019007118A patent/MY203401A/en unknown
- 2018-06-01 US US16/618,735 patent/US10959976B2/en active Active
- 2018-06-01 JP JP2020516785A patent/JP2020528075A/ja active Pending
- 2018-06-01 MX MX2019014409A patent/MX390786B/es unknown
- 2018-06-01 CA CA3065522A patent/CA3065522A1/en active Pending
- 2018-06-01 KR KR1020197038348A patent/KR20200016889A/ko not_active Ceased
- 2018-06-01 KR KR1020247036596A patent/KR20240162165A/ko active Pending
- 2018-06-01 WO PCT/US2018/035532 patent/WO2018222954A1/en not_active Ceased
- 2018-06-01 CN CN201880049345.2A patent/CN111201014A/zh active Pending
- 2018-06-01 KR KR1020237033870A patent/KR102726728B1/ko active Active
- 2018-06-01 BR BR112019025286-0A patent/BR112019025286A2/pt not_active Application Discontinuation
- 2018-06-01 AU AU2018278332A patent/AU2018278332B2/en active Active
-
2019
- 2019-12-02 PH PH12019502723A patent/PH12019502723A1/en unknown
-
2020
- 2020-05-19 US US16/877,717 patent/US10912754B2/en active Active
-
2021
- 2021-03-25 US US17/212,079 patent/US11648232B2/en active Active
-
2023
- 2023-05-12 US US18/316,841 patent/US11865098B1/en active Active
- 2023-12-08 US US18/534,234 patent/US20240180866A1/en not_active Abandoned
-
2024
- 2024-02-20 US US18/582,125 patent/US20240189270A1/en not_active Abandoned
- 2024-12-17 US US18/983,605 patent/US20250114322A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528075A5 (enExample) | ||
| Jordan et al. | Adult obstructive sleep apnoea | |
| Hoekema et al. | Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review | |
| Scherr et al. | Definition of an effective oral appliance for the treatment of obstructive sleep apnea and snoring: a report of the American Academy of Dental Sleep Medicine | |
| Andrade et al. | The role of physical exercise in obstructive sleep apnea | |
| Sutherland et al. | Efficacy versus effectiveness in the treatment of obstructive sleep apnea: CPAP and oral appliances | |
| Aarab et al. | Oral appliance therapy versus nasal continuous positive airway pressure in obstructive sleep apnea: a randomized, placebo-controlled trial | |
| Sutherland et al. | Recent advances in obstructive sleep apnea pathophysiology and treatment | |
| JP2016523862A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| Banhiran et al. | Adjustable thermoplastic mandibular advancement device for obstructive sleep apnea: outcomes and practicability | |
| JP2017526693A5 (enExample) | ||
| JP2017105861A5 (enExample) | ||
| MY207444A (en) | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2019507786A5 (enExample) | ||
| Diaz-Abad et al. | Use of volume-targeted non-invasive bilevel positive airway pressure ventilation in a patient with amyotrophic lateral sclerosis | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| e Cruz et al. | Sexsomnia and REM-predominant obstructive sleep apnea effectively treated with a mandibular advancement device | |
| Kieff et al. | Same-day discharge for selected patients undergoing combined nasal and palatal surgery for obstructive sleep apnea | |
| Akinnusi et al. | Emerging therapies for obstructive sleep apnea | |
| Shaarawy et al. | Assessment of the effect of bariatric surgery on severe obstructive sleep apnea patients not tolerating CPAP therapy | |
| Raoof et al. | Self‐reported oral moistening disorders in obstructive sleep apnoea: A scoping review | |
| WO2023231346A1 (zh) | N1-二氢咖啡酰基-n10-咖啡酰基亚精胺在制备药品、保健品或功能食品中的应用 | |
| Patel | Hypnic headache: a review of 2012 publications |